| Abstrakt: |
Nanostructured lipid carriers (NLCs) were developed and tested to increase bilastine (BT) bioavailability for allergic rhinitis treatment. Melt emulsification sonication constructed these adaptive nanostructured lipid carriers from bilastine (BT), Compritol 888 ATO, stearic acid, glyceryl monostearate (GMS), and Precirol ATO 5 (glyceryl palmitostearate). Nanostructured lipid carriers were added to a magnetic stirrer. NLCs were observed for surface charge, size distribution, and entrapment efficiency (EE%). To characterize the nanostructured lipid carriers, Fourier transform infrared, zeta potential, particle size, ex vivo permeation, in vitro drug release, and stability tests were performed. Polydispersity index and zeta potential of nanostructured lipid carriers were 0.201 ± 0.01 and − 24.01 mV, respectively, with an average hydrodynamic diameter of 95.30 ± 0.55 nm. On average, NLCs had an entrapment efficiency of 92.34 ± 1.4%. Ex vivo BT permeability was 5.86 times greater in the F-9 formulation than in the pure medication. The nanostructured lipid carriers increased BT bioavailability and antihistamine action, according to physicochemical characteristics and in vitro and in vivo characterizations. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink